Form 4: 4D Molecular Therapeutics CEO David Kirn Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
David Kirn, CEO of 4D Molecular Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- On June 24, 2024, David Kirn, the CEO of 4D Molecular Therapeutics, exercised stock options to acquire 12,930 shares of common stock at a price of $14.42 per share.
- Simultaneously, Kirn sold 12,930 shares of common stock at a weighted average price of $23.1022 per share, with individual sales prices ranging from $22.69 to $23.36.
- These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on March 21, 2024.
- Following these transactions, Kirn directly owns 1,059,153 shares of 4D Molecular Therapeutics common stock and holds options to purchase 577,070 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports transactions executed under a pre-existing plan. There is no indication of positive or negative implications for the company.
Industry Context
This filing is a routine disclosure of insider transactions and provides transparency to investors regarding executive stock ownership and trading activity. It is common for executives to utilize 10b5-1 trading plans to manage their stock sales and avoid accusations of insider trading.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the number of shares outstanding.
Key Dates
| Date | Description |
|---|---|
| 03/21/2024 | Date of adoption of the 10b5-1 trading plan by the Reporting Person. |
| 06/24/2024 | Date of the transaction involving the exercise of stock options and sale of common stock. |
| 06/26/2024 | Date of signature of the Form 4 filing. |
| 12/10/2033 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.